adults are eligible for semaglutide for weight loss, and while the authors correctly cite access and cost as important barriers, there are other significant limitations and risks, says letter author Vanita Rahman, MD, DipABLM, internal medicine and lifestyle medicine doctor with the Physicians Committee for Responsible Medicine, a public health advocacy nonprofit
Current evidence suggests the class as a whole requires monitoring, though some studies have noted variations between different drugs
increasing the expression of mitofusin 1 (MFN1) and mitofusin 2 (MFN2)
IV therapy is beneficial for hydration, vitamins, and recovery, but it is not a substitute for proper sleep, diet, or consuming enough water